Dr. Avani Dholakia Rao, MD

Dr. Rao practices at Inova Fairfax Hospital - Unit in Falls Church, Virginia.

Dr. Rao's NPI, 1295006567, was assigned on January 19, 2012. Dr. Rao graduated from The Johns Hopkins University School of Medicine in 2014. Dr. Rao's Maryland license number on file is D87017.

Dr. Rao's primary practice is Inova Fairfax Hospital - Unit, at 3300 Gallows Rd, Falls Church, VA 22046 in Falls Church City. The practice phone is (703) 698-3659.

Dr. Rao's primary practice is Inova Fairfax Hospital - Unit in Falls Church, Virginia. Dr. Rao is also affiliated with Inova Fairfax Hospital. The medical group on file is Radiation Oncology Associates of Northern Virginia. Dmand AI also links Dr. Rao to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rao practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rao's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rao is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Rao's licenses on file in 2 states: Maryland and Virginia.

Dmand AI lists breast cancer radiation, cancer radiation-upper GI, cervical cancer radiation, colorectal cancer radiation, lung cancer radiation, lymphoma radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Rao treats.

CMS data shows 2,370 Medicare services from Dr. Rao across 19 procedure codes in 2024, for 647 Medicare patients. Medicare paid $176,011 for them.

CMS counts 647 Medicare patients who saw Dr. Rao in 2024. The largest group is 65 to 74, with 289 patients. 75% of them have cancer, and 75% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rao's median patient age at 64, with 56% women.

In 2024, Dr. Rao wrote 61 Medicare Part D claims for 35 patients. 82% of them were for generic drugs. CMS names the drug for 23 of them, across 2 drugs with 11 or more claims each, at $348 in total drug cost. In 2020, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Rao for performance year 2024, reported as part of a group. Dr. Rao accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rao as offering telehealth.

Dmand AI links 29 papers to Dr. Rao, published from 2015 to 2024. 2018 was the busiest year, with 6. The most frequent topics are Pancreatic Neoplasms, Radiation Injuries and Radiosurgery. Dr. Rao has published most often in Int J Radiat Oncol Biol Phys. Dr. Rao's most frequent co-authors are Stephanie Alicia Terezakis, MD, Matthew Michael Ladra and Joseph M. Herman, MD.

Dmand AI links Dr. Rao to 2 clinical trials. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases.

CMS Open Payments shows 22 general payments to Dr. Rao from 11 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 67% of the total. Daiichi Sankyo Inc. paid the most, $6,917.

Dmand AI lists 2 awards for Dr. Rao, most recently Chief Resident in 2019.

Dr. Rao graduated from The Johns Hopkins University School of Medicine in 2014.

Dr. Rao is in network with 19 carriers, including United Healthcare, CareFirst BlueCross BlueShield and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.